Akeso stock

9926 · HKEX · HKD

Compare Akeso
$56.70Change from previous close: −7.05%Absolute change: −$4.30

Close · November 20, 2026

Price history

−49.87% over the period

1 year: from $113.10 (November 20, 2025) to $56.70 (November 20, 2026), −49.87%.

Show chart data

Closing prices adjusted for splits: the last close of each month.

DateClose
November 20, 2026$56.70
October 30, 2026$81.50
September 30, 2026$108.70
August 31, 2026$89.90
July 31, 2026$93.95
June 30, 2026$88.05
May 29, 2026$118.10
April 30, 2026$135.80
March 31, 2026$130.20
February 27, 2026$106.90
January 30, 2026$110.40
December 31, 2025$113.10
November 28, 2025$122.90
November 20, 2025$113.10

At a glance

  • The company

    Research, develop, manufacture and commercialize antibody drugs for cancer, cardiovascular and inflammatory diseases

  • Latest results

    Quarter to June 30, 2026 · EPS -¥0.46

TickerLandia's take on Akeso

Analysis calculated by TickerLandia from financial statements and prices, with public rules. Not investment advice. How we analyse stocks

Where the price stands

52-wk low$56.10
52-wk high$156.00

−63.65% from the 52-week high

Analysts · 23 analysts

Average target$138.56+144.38% vs. price

Buy 21 · Hold 2 · Sell 0 · Strong buy

TickerLandia Fingerprint: Akeso

Compared with similar companies: very weak momentum and very high risk.

Financials and price compared with 61 companies in the biotechnology industry, worldwide. Momentum and risk compared with 1,074 Asia-Pacific stocks.

Position in the group from 0 to 100 (100 = highest value): it describes, it does not rate. Tap a row for the metrics. Calculated on November 22, 2026. An indicator calculated by TickerLandia from financial statements and market data. How it is calculated

Valuation

Akeso is pricier than similar companies

Akeso's Forward P/E: 45.4, +43% against the median of a group of 10 similar companies (31.7).

Compared with 10 similar companies

Akeso's metrics compared with similar companies
MetricAkesoPosition in the groupBand
Forward P/E45.4High
Operating margin-30.7%Low
ROE-13.6%Low
Debt/equity0.60High
Price/book5.24Middle

Grey band: the middle half of the group; tick: the median; dot: Akeso. All multiples and dividends

TickerLandia analysisHow it is calculated

The financials

The business in numbers

Revenue

¥1.81B

Latest quarter · Q2 2026

Net income

-¥424.22M

Latest quarter · Q2 2026

Quarterly net margin

-23.5%

Latest quarter · Q2 2026

Numbers and valuation

Full valuation
Market cap
$53.36B
EPS
-$1.17
Volume
17.83M
Daily trading
€125.28M
Dividend yield
0.00%

How Akeso is changing

All results
  • Revenue grew 53.9% a year on average over the last 3 years

  • Operating margin rose from −183.6% to −32.5%

  • Shares outstanding up 43.6% in 5 years

Returns

Akeso returns

$1,000 invested in Akeso 5 years ago, on November 22, 2021, would be worth $1,105 today: +10.53% in total, +2.02% per year. This is the price return only: dividends are excluded.

PeriodAkesoHang Seng$1,000 becomes
1 month−37.96%−6.10%$620
6 months−50.70%−12.63%$493
Year to date−49.87%−12.56%$501
1 year−49.87%−13.26%$501
3 years+23.39%+26.06%$1,234
5 years+10.53%−10.18%$1,105

Over the last 6 months it has done better than 2% of the stocks in the Healthcare sector.

Price only, without dividends. Calculate your investment

The chart in detail

Akeso: technical analysis

Akeso is in a downtrend: the price is below its 50- and 200-session moving averages, and the 200-session average is falling. The price is 67.9% below its all-time closing high ($176.90, August 22, 2025).

Trend
Downward
RSI (14 sessions)
26
Below 30: a strong fall in a short time
vs 200-session average
−45.19%

Active signals

  • RSI below 30: the stock has fallen a lot in a short time.

    since November 16, 2026

Support and resistance

Price areas where Akeso has stopped several times in the last year. They describe the chart; they are not forecasts.

  1. Resistance$91.68+61.69%5 touches, last on November 10, 2026
  2. Resistance$86.35+52.29%2 touches, last on September 1, 2026
  3. Resistance$81.52+43.78%2 touches, last on June 22, 2026
  4. Last price$56.70
  5. No support below: the price is near the lows of the year

Volatility and risk

Over the last year it has moved more than the Hang Seng.

Beta (1 year) vs Hang Seng
1.33
Volatility (60 sessions, annualised)
90.2%
Largest fall in the last year
−62.45%

Close of November 20, 2026. Descriptive data calculated on daily prices: it describes the chart and is not investment advice. Beta and volatility describe the last year and can change a lot from one year to the next. How we calculate it

Akeso: seasonality

Average monthly price change over 7 years

−0.4%Jan+1.8%Feb+0.7%Mar+4.2%Apr−2.1%May+7.8%Jun+8.5%Jul−1.3%Aug+6.1%Sep+0.4%Oct+10.2%Nov+2.9%Dec

Over the last 7 years, the strongest month for Akeso has been November: +10.22% on average, positive in 6 years out of 6. The weakest has been May: −2.13% on average, positive in 2 years out of 7.

Show chart data
MonthAverageMedianPositive years
January−0.35%−1.11%3 of 6
February+1.82%−3.12%2 of 6
March+0.69%+0.02%3 of 6
April+4.15%+5.18%5 of 6
May−2.13%−2.84%2 of 7
June+7.79%+1.29%4 of 7
July+8.49%+6.70%4 of 7
August−1.28%−4.06%3 of 7
September+6.09%+4.50%4 of 7
October+0.37%−8.45%3 of 7
November+10.22%+10.97%6 of 6
December+2.90%−7.45%2 of 6

Price change only, dividends excluded. Past seasonality does not predict future moves.

The company

Akeso and its competitors

Based in Zhongshan, China, Akeso, Inc. was founded in 2012 and develops antibody drugs for cancer and immune-related diseases. Its research, development, manufacturing and commercialization activities cover markets worldwide. The pipeline centers on bispecific antibodies, including AK104, a PD-1/CTLA-4 candidate for cervical, gastric, lung and liver cancers, and AK112, a PD-1/VEGF candidate for several solid tumors. Other programs include AK117, a CD47 antibody for hematologic cancers, and AK101, AK111, AK120 and AK102, targeting psoriasis, ulcerative colitis, ankylosing spondylitis, atopic dermatitis and hypercholesterolemia.

Headquarters
Zhongshan, China
Employees
4,082
Founded
2012
Chief executive
Yu Xia
Akeso and its competitors
CompanyMarket capOperating marginP/E (trailing 12 months)6 months
Akeso9926$6.81B-30.7%—−50.70%
Genscript Biotech1548$8.77B14.9%—+112.07%
Haisco Pharmaceutical Group002653$8.97B21.1%44.1+0.54%
ALTEOGEN196170$9.05B47.2%97.1−36.93%
3SBio1530$4.56B60.3%3.90−34.08%
Pharmaron Beijing300759$10.59B14.0%39.3+44.36%

Same industry or related industries, similar size. Compare Akeso with its competitors · Full profile